In January, the U.S. FDA said a preliminary review showed no evidence of such a link, though the agency said it could not rule out that ‘a small risk may exist.’
The Ontario College of Pharmacists has announced it will take steps to address preferred provider networks—including exploring stronger regulatory responses.
Diltiazem used for ventricular rate control in patients with atrial fibrillation inhibits apixaban and rivaroxaban elimination, possibly causing overanticoagulation.
